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Chitinases have an important role in the defense of organisms against chitin-containing
parasites. An acidic mammalian chitinase (AMCase) has been detected in epithelial cells in
lung tissue samples taken from patients with asthma as well as in conjunctival epithelium
of patients with inﬂammatory ocular diseases. Particularly, elevated AMCase activity has
been observed in ocular tissues of patients with vernal keratoconjunctivitis, seasonal aller-
gic conjunctivitis, and in patients affected by dry eye syndrome. This enzyme is induced
via a TH2-speciﬁc, IL-13-dependent pathway. AMCase may thus be a key mediator of
IL-13-induced responses in TH2-driven inﬂammatory ocular diseases.
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INTRODUCTION
Polysaccharides are present in all organisms, mostly for struc-
tural purposes. Chitin is plentiful in the structural coatings of
fungi, insects, and parasitic nematodes, but it is not produced
in mammals. Chitin, the linear polymer of β-1,4 linked β-N -
Acetyl-glucosamine (GlcNAc), is the most abundant biopolymer
in marine ecosystems and, after cellulose, the second most copi-
ous polysaccharide in nature. Since chitin seems not to be made
in mammals, it was initially assumed that chitinases would also be
absent, being restricted to species that do contain the polymer.
However, the host defense against chitin-containing pathogens
includes the production of chitinases. Chitinases are endo-β-
1,4 linked β-N -Acetyl-glucosaminidase, and recently, two dis-
tinct chitinases have been identiﬁed in humans, chitotriosidase
(Chit) expressed in phagocytes, and an acidic mammalian chiti-
nase (AMCase) expressed in gastrointestinal tract, in lung, and
conjunctiva. AMCase, 50 kDa protein, is a member of the gly-
cosyl hydrolase 18 family (EC 3.2.1.14) and has structural sim-
ilarity (Figure 1) with other glycosyl hydrolase 18 family mem-
bers, including the lectins Ym1 and Ym2, which are expressed in
macrophages, human cartilage glycoprotein-39 (HC-gp39), and
chitotriosidase (Muzzarelli, 2008). Chit and AMCase show chiti-
nase enzymatic activity, whereas other mammalian chitinases do
not possess this activity. Characteristically, the resistance to acidic
pH distinguishes AMCase from Chit, which has its optimum at
pH 6. On the contrary, AMCase has its optimum at pH 2 and 4 in
rodents and humans, respectively; AMCase is expressed in differ-
ent tissues such as stomach, lung, and salivary glands, and appears
to be associated with inﬂammatory diseases (Chou et al., 2006).
Chit, has been shown to be expressed togetherwith lysozyme in the
human lacrimal gland (Hall et al., 2008). This chitinase produced
by macrophages and neutrophils also has a role in innate immu-
nity (van Eijk et al., 2005). Since this chitinase was considered
more active in the control of chitin-containing pathogens, the
presence of measurable Chit activity in tears appears to support
the protection of the eye in both humans and mice, where the
chitotriosidase (CHIT ) gene is evolutionarily conserved (Gian-
francesco and Musumeci, 2004). In this context, it is interesting
to note that Chit, unlike bacterial chitinases, does not appear to
have any mucolytic activity (Sanders et al., 2007), and therefore
the lacrimal ﬁlm is not modiﬁed in its structure, maintaining the
integrity of visual function. Moreover, Hall et al. (2008) found
that recombinant Chit does not inhibit bacterial growth and does
not synergize with lysozyme on the growth of Gram-positive and
Gram-negative bacteria, and the antimicrobial activity appears to
be limited only to fungi. AMCase appears to play a key role as
ﬁrst responder of the immune system (Ramanathan et al., 2006),
both in the epithelial cells lining the nasal mucosa and other
contiguous conjunctival cells. When the epithelial cells are stim-
ulated against non-existent parasites through a mechanism that
induces an IL-13 response, they can produce chitinases, which
represent a marker of both innate immunity and inﬂammatory
response. In addition to the role in innate immune response, the
modulation of AMCase expression by speciﬁc inhibitors suggests
a new pathway for controlling ocular inﬂammation. This arti-
cle seeks to provide a succinct review of ocular inﬂammation, a
rapidly changing area of visual science, focusing on the role of
chitinase.
AMCase AND BIOLOGICAL ACTIONS
One of the most important issues in chitinase biology relates
to our almost complete lack of understanding of the functions
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FIGURE 1 | Structure of humanAMCase in complex with allosamidin.
EC 3.2.1.14; source: EMBL–EBI (European Molecular Biology
Laboratory–European Bioinformatics Institute; www.ebi.ac.uk).
of these strongly conserved, and therefore presumably biolog-
ically important, enzymes in human subjects. Chitinases have
been studied most intensely in lower life forms, where they are
produced in signiﬁcant quantities byhosts defending against infec-
tions with chitin-containing organisms. This can be appropriately
considered part of the innate immune response against a chitin-
containing pathogen. AMCase contains a 30-kDa N-terminal
catalytic domain that can hydrolyse chitin, and it has recently
been identiﬁed both in human gastrointestinal tract and lung.
Chitinase production can also play a key role in the life cycle of
chitin-containing fungi and parasites, where they control growth
and molting, and can be used by pathogens to invade or exploit
chitin-containing structures to complete their lifecycle in the host.
AMCase represents a product of genes on mouse chromosome3
and human chromosome 1 at p13.1–p21.3. The enzyme is acid
stable, with a pH optimum of 2.0, and its appears to be adapted
to function in the extreme environment of the stomach where it
may play a role in defense and/or digestion of chitin-containing
organisms. Recently, Goedken et al. (2011) have demonstrated
that AMCase is active with appropriate pH proﬁle showing that its
activity at pH 2.0 was fourfold the activity obtained at higher pH
(5.2 and 7.5). This enzymemight also have non-chitin-related bio-
logic effector properties because an AMCase-like protein has been
reported to possess ﬁbroblast growth-promoting activity (Guop-
ing et al., 1997), and AMCase has been implicated in host defenses
and food processing (Muzzarelli, 2008). Further, AMCase plays
a key role in TH2 inﬂammation (Zhu et al., 2004). AMCase is
induced at sites of inﬂammation (e.g., parasitic infections) and
remodeling. This raises the possibility that this enzyme plays active
roles in human antiparasite and antiinfective defense and repair
responses. Probably AMCase plays a role as sentinel that trigger
responses to parasites, infections, and/or antigen challenge, act-
ing directly as chemotactic agents or indirectly by inducing other
chemokines that attract eosinophils and T cells to sites of par-
asitic infection, in other words AMCase maybe modulate tissue
inﬂammation, immunity, and remodeling (Zhu et al., 2004).
AMCase AS A POTENTIAL THERAPEUTIC MOLECULE
A role for AMCase in asthma pathophysiology has been sug-
gested following the demonstration that AMCase expression is
increased in the lungs of ovalbumin sensitized and challengedmice
that develop airway hyperresponsiveness, compared with control
animals challenged with phosphate-buffered saline (Zhu et al.,
2004). In this animal model of asthma, AMCase is expressed in
both airway epithelial cells and alveolar macrophages. Elevated
expression of AMCase was also observed in lung tissue from asth-
matic patients when compared with normal subjects (Zhu et al.,
2004). AMCase is produced in human epithelial cells of lower
airways and conjunctiva via aTH2-speciﬁc, IL-13-dependentpath-
way and seems to be associated with asthma and allergic ocu-
lar pathologies. AMCase has also been proposed as a potential
therapeutic target in TH2-mediated inﬂammation (Donnelly and
Barnes, 2004). In fact, the inhibition of AMCase activity by the
chitinase inhibitor allosamidin decreased the number of inﬂam-
matory cells in the bronchoalveolar lavage ﬂuid of ovalbumin
sensitized and challenged mice, and reduced asthma symptoms
(Zhu et al., 2004. Interestingly, the same response was obtained
using antisera against AMCase given in the airways by aerosol
(Zhu et al., 2004). The understanding of the role of AMCase in
allergic disease is only at its beginning and many issues open new
possibilities for its control using speciﬁc inhibitors of AMCase
activity or modulating its expression. In patients with vernal ker-
atoconjunctivitis (VKC) and with seasonal allergic conjunctivitis
(SAC) the level of AMCase activity in the tears was found signiﬁ-
cantly elevated when compare to healthy controls and the highest
levels were found in VKC (Musumeci et al., 2008). When RNA
was extracted by conjunctival epithelial cells of these patients,
quantitative Real Time PCR measurement conﬁrmed that mRNA
expression correlates with tear AMCase activity and the expres-
sion was signiﬁcantly higher in VKC and SAC. Also receiver
operating characteristic (ROC) analysis demonstrated that the
sensitivity and speciﬁcity of AMCase measurement were 100%,
addressing the use of AMCase assay in the biochemical diagno-
sis of VKC and SAC (Musumeci et al., 2008).Recent studies in
rabbits, where a uveitis was induced by LPS injection into the
eye’s anterior chamber, conﬁrmed that increased AMCase activ-
ity was measurable in tears and that epithelial cells of conjunctiva
express speciﬁc mRNA (Bucolo et al., 2008).Further, it was pre-
viously demonstrated in experimental model of mouse asthma,
the inﬂammatory reaction induced by LPS was controlled by the
chitinase inhibitor and glucocorticoids, instilled at 3 h interval
in conjunctival sac. In dry eye syndrome, another non-allergic
Frontiers in Pharmacology | Inﬂammation Pharmacology July 2011 | Volume 2 | Article 43 | 2
Bucolo et al. Acidic mammalian chitinase and the eye
ocular pathology, an increased AMCase activity was documented
and the speciﬁc mRNA expressed by epithelial conjunctival cells
(Musumeci et al., 2009). In this pathology the eye inﬂammation
can be ascribed to a common mechanism mediated by AMCase,
via a TH2-speciﬁc, IL-13 dependent way. In summary, AMCase
may be considered an important mediator in the pathogenesis
of TH2 inﬂammation eye’s diseases, suggesting its potential diag-
nostic and therapeutic utility. Inhibition of AMCase, decreasing
the inﬂammation in the mice that overexpressed IL-13, suggests
a loop in the modulatory effect of AMCase in allergic asthma as
well in allergic conjunctivitis. In fact, AMCase enzyme inhibition
with allosamidin does not alter the level of expression of IL-13
receptors, but inhibits IL-13 from stimulating the expression of
several chemotactic factors, typical of allergic inﬂammation and
asthma (Romagnani, 2002; Zhu et al., 2002). We showed that, in
endotoxin-induced uveitis in rabbit, the production of AMCase in
tears was modulated by glucocorticoids treatment and the inhi-
bition of activity by allosamidin, a chitinase inhibitor, caused an
effective reductionof the inﬂammation clinical score (Bucolo et al.,
2008). These data are in accordance with the ﬁndings generated
from other laboratories, Homer et al. (2006) observed that expres-
sion of AMCase is upregulated in response to allergen exposure
or IL-13-induced inﬂammation in mouse lung and allosamidin
strongly inhibits AMCase. Furthermore, recently Matsumoto et al.
(2009) showed that allosamidin anddemethyl allosamidin, showed
a potent anti-inﬂammatory activity in allergicmousemodels, even
though the mechanism of action remains unclear. As mentioned
before, we found (Musumeci et al., 2008) an overexpression of
AMCase mRNA in epithelial conjunctival cells during VKC and
SAC, suggesting that the activity of AMCase could be used as a
differentiate parameter for diagnosis (AMCase activity higher in
VKC than in SAC). In these studies, it was clear that AMCase
did not directly induce a TH2 cytokine response, but mediated or
modulated the effector response of IL-13 (a cytokine produced by
TH2 cells).Moreover, it seems that AMCase activity is required for
the increased production of the chemoattractants of the inﬂam-
matory cells such as monocyte chemoattractant proteins (MCPs)
and eotaxins. From these considerations, it seems evident that the
expression of AMCase and theTH2-induced inﬂammation are dri-
ven by a sequential mechanism that is attenuated by inhibitors of
chitinase (Figure 2).
CONCLUSION
Increases in acidic mammalian chitinase levels are a poten-
tially important downstream effect of IL-13 stimulation in TH2-
oriented immune responses to pathogens and parasites AMCase
FIGURE 2 | Model of AMCase-mediated ocular inflammation.
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seems to be a key mediator of IL-13-induced responses in TH2-
driven immune-inﬂammatory eye diseases with a lofty implica-
tion in ocular allergy conditions as well as in dry eye syndrome.
However, the immuno-regulatory function of AMCase is not
completely clear so far, therefore translational research may be
warranted in order to elucidate that.
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